Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies

被引:14
作者
Del Campo, Jose A. [1 ,2 ]
Romero-Gomez, Manuel [1 ,2 ]
机构
[1] Valme Univ Hosp, Digest Dis, Seville 41014, Spain
[2] Valme Univ Hosp, CIBERehd, Seville 41014, Spain
关键词
Hepatitis C virus; Lipid metabolism; Direct acting antiviral agents; Genetic interaction; Sofosbuvir; ANTIVIRAL SIGNALING PROTEIN; LOW-DENSITY; APOLIPOPROTEIN-E; DIACYLGLYCEROL ACYLTRANSFERASE-1; VIROLOGICAL RESPONSE; COMBINATION THERAPY; INNATE IMMUNITY; VIRAL GENOTYPE; LIVER-DISEASE; SERUM-LIPIDS;
D O I
10.3748/wjg.v21.i38.10776
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
It is well established that hepatitis C virus (HCV) infection and replication relies on host lipid metabolism. HCV proteins interact and associate with lipid droplets to facilitate virion assembly and production. Besides, circulating infective particles are associated with very low-density lipoprotein. On the other hand, higher serum lipid levels have been associated with sustained viral response to pegylated interferon and ribavirin therapy in chronic HCV infection, suggesting a relevant role in viral clearance for host proteins. Host and viral genetic factors play an essential role in chronic infection. Lipid metabolism is hijacked by viral infection and could determine the success of viral replication. Recently development of direct acting antiviral agents has shown a very high efficacy (> 90%) in sustained viral response rates even for cirrhotic patients and most of the viral genotypes. HCV RNA clearance induced by Sofosbuvir has been associated with an increased concentration and size of the low-density lipoprotein particles. In this review, host genetic factors, viral factors and the interaction between them will be depicted to clarify the major issues involved in viral infection and lipid metabolism.
引用
收藏
页码:10776 / 10782
页数:7
相关论文
共 50 条
[41]   Hepatitis C virus: Enslavement of host factors [J].
Sharma, Geetika ;
Raheja, Harsha ;
Das, Saumitra .
IUBMB LIFE, 2018, 70 (01) :41-49
[42]   Host–virus interactions in hepatitis B and hepatitis C infection [J].
Sachiyo Yoshio ;
Tatsuya Kanto .
Journal of Gastroenterology, 2016, 51 :409-420
[43]   Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance [J].
Bang, Bo-Ram ;
Li, Meng ;
Tsai, Kuen-Nan ;
Aoyagi, Haruyo ;
Lee, Shin-Ae ;
Machida, Keigo ;
Aizaki, Hideki ;
Jung, Jae U. ;
Ou, Jing-Hsiung James ;
Saito, Takeshi .
JOURNAL OF VIROLOGY, 2019, 93 (08)
[44]   Current and Future Therapies for Hepatitis C Virus Infection [J].
Liang, T. Jake ;
Ghany, Marc G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1907-1917
[45]   Evolution of efficacious pangenotypic hepatitis C virus therapies [J].
Ashraf, Muhammad Usman ;
Iman, Kanzal ;
Khalid, Muhammad Farhan ;
Salman, Hafiz Muhammad ;
Shafi, Talha ;
Rafi, Momal ;
Javaid, Nida ;
Hussain, Rashid ;
Ahmad, Fayyaz ;
Shahzad-Ul-Hussan, Syed ;
Mirza, Shaper ;
Shafiq, Muhammad ;
Afzal, Samia ;
Hamera, Sadia ;
Anwar, Saima ;
Qazi, Romena ;
Idrees, Muhammad ;
Qureshi, Sohail A. ;
Chaudhary, Safee Ullah .
MEDICINAL RESEARCH REVIEWS, 2019, 39 (03) :1091-1136
[46]   The New Era of Hepatitis C Virus Therapy [J].
Al-Judaibi, Bandar .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2015, 21 (06) :345-354
[47]   Lipid droplets and hepatitis C virus infection [J].
McLauchlan, John .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2009, 1791 (06) :552-559
[48]   Evolving therapies for hepatitis C virus in chronic kidney disease: the beginning of a new era [J].
Gordon, Craig E. ;
Nader, Claudia .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2017, 26 (02) :129-135
[49]   The Role of Lipid Metabolism in Influenza A Virus Infection [J].
Zhou, Yong ;
Pu, Juan ;
Wu, Yuping .
PATHOGENS, 2021, 10 (03) :1-11
[50]   Role of Some Predominant Host Immunomodulators' Single Nucleotide Polymorphisms in Severity of Hepatitis B Virus and Hepatitis C Virus Infection [J].
Rehman, Shafiq Ur ;
Rauf, Mahd ;
Abbas, Zaigham ;
Hamed, Muhammed Haroon ;
Qadri, Ishtiaq .
VIRAL IMMUNOLOGY, 2016, 29 (10) :536-545